잠시만 기다려 주세요. 로딩중입니다.

Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis

Integrative Medicine Research 2020년 9권 3호 p.8 ~ 8
Pang Wentai, Liu Zhi, Li Nan, Li Yuyun, Yang Fengwen, Pang Bo, Jin Xinyao, Zheng Wenke, Zhang Junhua,
소속 상세정보
 ( Pang Wentai ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Liu Zhi ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Li Nan ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Li Yuyun ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Yang Fengwen ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Pang Bo ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Jin Xinyao ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Zheng Wenke ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center
 ( Zhang Junhua ) - Tianjin University of Traditional Chinese Medicine Evidence-Based Medicine Center

Abstract


Background: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19.

Method: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis.

Result: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR?=?0.47, 95% CI=[0.32, 0.69], P?
Conclusion: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required.

키워드

Coronavirus disease 2019; Integrative medicine; Chinese medical drug; Systematic review; Core outcome set; Meta analysis

원문 및 링크아웃 정보

등재저널 정보